Matt Pauls

Insider profile

Currently holds positions in Strongbridge Biopharma plc, Zyla Life Sciences and Savara Inc

Performance

Overall performance
2.8

Performance over holding periods
4.2
30 days 90 days 120 days
Average return -2% 8.2% 15.1%
Success rate 21% 68% 82%
Transactions
8 62% Buy
34 71% Buy
47 69% Buy

Performance for realised trades
4.4
Average return 331%
Success rate 73%
Average holding period 220
Transactions 28

Positions

Position Company Period
Chief Executive Officer, Director Strongbridge Biopharma plc Aug. 1, 2014 -
Director Zyla Life Sciences Jan. 31, 2019 -
Independent Director Savara Inc Nov. 2, 2015 -
Chief Commercial Officer Insmed Incorporated April 1, 2013 - Dec. 1, 2014

Matt Pauls's trades of Pelthos Therapeutics Inc's stock


Loading...
Purchase Sale Planned purchase Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
67.39
Quantity 5,937
Value US$400,094
Transaction date
Proposed sale
Price
3.31
Quantity 54,702
Value US$180,800
Transaction date
Sale
Price
3.31
Quantity 54,702 -3.4%
Value US$180,828
Transaction date
Sale
Price
4.71
Quantity 84,000 -6.1%
Value US$395,900
Transaction date
Proposed sale
Price
4.74
Quantity 84,000
Value US$398,000
Transaction date
Purchase
Price
1.06
Quantity 6,500 +1.7%
Value US$6,889
Transaction date
Purchase
Price
1.10
Quantity 10,000 +2.7%
Value US$10,954
Transaction date
Purchase
Price
1.07
Quantity 2,150 +0.6%
Value US$2,290
Transaction date
Purchase
Price
1.11
Quantity 10,000 +2.8%
Value US$11,100
Transaction date
Purchase
Price
1.10
Quantity 10,000 +2.9%
Value US$11,000
Transaction date
Planned purchase
Price
1.82
Quantity 27,400 +9.8%
Value US$49,871
Transaction date
Planned purchase
Price
2.07
Quantity 24,100 +9.4%
Value US$49,938
Transaction date
Planned purchase
Price
1.74
Quantity 28,700 +12.6%
Value US$50,038
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value
Number of shares Price Value Details
2026-07-07 2026-07-02 PlS Planned sale
40,692 +23.5%
307.41
US$1,329,035
40,692 +23.5% 307.41 US$1,329,035
2026-07-07 2026-07-02 PlS Planned sale
63,012 -0.5%
491.62
US$1,276,539
63,012 -0.5% 491.62 US$1,276,539
2026-04-06 2026-04-02 PlS Planned sale
86,320 +37.0%
38.70
US$1,751,576
86,320 +37.0% 38.70 US$1,751,576
2026-04-06 2026-04-02 PlS Planned sale
415 -2.6%
20.52
US$8,514
415 -2.6% 20.52 US$8,514
2025-03-31 2025-03-28 S Sale
5,937 -47.7%
71.55
US$424,797
5,937 -47.7% 71.55 US$424,797
2025-03-28 2025-03-28 PrS Proposed sale
5,937
67.39
US$400,094
5,937 67.39 US$400,094
2024-12-16 2024-12-16 PrS Proposed sale
54,702
3.31
US$180,800
54,702 3.31 US$180,800
2024-12-16 2024-12-16 S Sale
54,702 -3.4%
3.31
US$180,828
54,702 -3.4% 3.31 US$180,828
2023-12-29 2023-12-28 S Sale
84,000 -6.1%
4.71
US$395,900
84,000 -6.1% 4.71 US$395,900
2023-12-28 2023-12-28 PrS Proposed sale
84,000
4.74
US$398,000
84,000 4.74 US$398,000
2021-12-08 2021-12-08 B Purchase
6,500 +1.7%
1.06
US$6,889
6,500 +1.7% 1.06 US$6,889
2021-12-02 2021-12-02 B Purchase
10,000 +2.7%
1.10
US$10,954
10,000 +2.7% 1.10 US$10,954
2021-11-22 2021-11-19 B Purchase
2,150 +0.6%
1.07
US$2,290
2,150 +0.6% 1.07 US$2,290
2021-11-22 2021-11-19 B Purchase
10,000 +2.8%
1.11
US$11,100
10,000 +2.8% 1.11 US$11,100
2021-11-22 2021-11-18 B Purchase
10,000 +2.9%
1.10
US$11,000
10,000 +2.9% 1.10 US$11,000
2021-04-19 2021-04-19 PP Planned purchase
27,400 +9.8%
1.82
US$49,871
27,400 +9.8% 1.82 US$49,871
2021-03-22 2021-03-22 PP Planned purchase
24,100 +9.4%
2.07
US$49,938
24,100 +9.4% 2.07 US$49,938
2021-02-23 2021-02-22 PP Planned purchase
28,700 +12.6%
1.74
US$50,038
28,700 +12.6% 1.74 US$50,038